![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, December 23, 2018 3:24:53 PM
According to this article, or the author’s assessment rather, the Amyloid theory looks to live or die based on BIIB’s candidates. They remain the last bastion of the theory.
Couple interesting points to consider when analyzing the overall landscape:
If the Amyloid theory is put to rest, once and for good, this allows the stuffy, scientific, closed up room to finally throw open the windows to ventilate and inhale new theories.
(The reigning Don has to die before they can kiss the new ring. Guess I’m a wartime consigliere.)
Seeing as how the BP/FDA has ruled the AD space research like Pol Pot in “re-education” of everyone to this way of thinking (Amyloid theory) for the last 30 years, it will now take some real re-education on the part of the scientific and bureaucratic communities to usher in anything new, be it sigma 1 receptor agonism, or some other approach. I think this step is underway. US does not want to finish last in this race - the one in which, if you’re not first...you’re last. There is no second, third...place.
I think Biogen has the business savvy to have studied the field it is playing in and can see that further development of these drugs - which is only being CONSIDERED at this point, is a dreadful waste of resources. The article states that the chances of BAN2041, and elenbecestat (both Eisai collabs are less promising than their solo effort aducanumab. That’s interesting and could suggest a possible break with Eisai is in the offing as some here have suggested.
If Biogen wishes to remain in the AD space, it will have to put all of its faith in their solo drug or perhaps scan for something new with promise. They probably have a good handle on what their drug will do (pass/fail) based on previous Amyloid failures. They have also upped their rhetoric on “bigger, later stage acquisitions” in last couple earnings calls via their CFO.
This is a pre-2019 walkback from the 2018 year of data in which they promised investors the world. Gee - we catch all kind of Hell for indicating our drug has any potential based on science and sample size...TAKE A LOOK AT BIIB’s sample size (10!) and results in relation to placebo. Whoosh!
Recall how many times I reiterated that the timing of their PR’s indicated they had blinked and given away their game? I speculated that a deal would follow when we had runners in scoring position and PDD was quickest way to get there. I said they would put pressure by holding CAPS LOCK on our share price in order to keep the price down so that we could not tap Cantor for additional funding at a decent rate. We would see the message board in full court press negative posts about our science, management, fire Missling and the Board - in order to get that poison pill protection knocked out (Hudsucker Proxy!). All has come to pass.
Now, with runners in scoring position, PDD is moving along “swiftly” and AD is enrolling, Rett is approved...the rhetoric coming from the investor sites is looking capitulation-y. As predicted. Not a surprise at all. If PDD returns positive results, the price of poker goes sky high for a deal because we can easily finance everything else and MC goes up.
Mound visit coming. Hold! And expect bunches of replies indicating that this is delusional thinking and we are not on anybody’s radar (wink - THAT train is never late!)
GLTAL
Bio
Biogen's BAN2401 Not A Home Run Anymore, But Still Holds Some Promise $BIIB
https://seekingalpha.com/article/4229852
Recent AVXL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM